Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
A phase II study to assess the efficacy and safety of Surufatinib Combined With Toripalimab and Chemotherapy as a first-line treatment in patients with advanced non-squamous non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
DRUG: Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin
Progression Free Survival (PFS), up to 24 months
Objective response rate(ORR), up to 24 months|Disease control rate(DCR), up to 24 months|Overall Survival(OS), up to 24 months
A phase II study to assess the efficacy and safety of Surufatinib Combined With Toripalimab and Chemotherapy as a first-line treatment in patients with advanced non-squamous non-small cell lung cancer.